Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Return on Capital Employed (2021 - 2025)

Silence Therapeutics' Return on Capital Employed history spans 5 years, with the latest figure at 17.65% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 1560.0% to 17.65% in Q4 2025 year-over-year; TTM through Dec 2025 was 17.65%, a 1560.0% decrease, with the full-year FY2025 number at 14.44%, down 673.0% from a year prior.
  • Return on Capital Employed hit 17.65% in Q4 2025 for Silence Therapeutics, up from 22.19% in the prior quarter.
  • Over the last five years, Return on Capital Employed for SLN hit a ceiling of 13638.6% in Q2 2021 and a floor of 6999587.55% in Q4 2021.
  • Historically, Return on Capital Employed has averaged 1167021.49% across 5 years, with a median of 12.76% in 2022.
  • The widest YoY moves for Return on Capital Employed: up 699957478bps in 2022, down -431547361bps in 2022.
  • Tracing SLN's Return on Capital Employed over 5 years: stood at 6999587.55% in 2021, then skyrocketed by 100bps to 12.76% in 2022, then grew by 3bps to 12.39% in 2023, then soared by 83bps to 2.05% in 2024, then plummeted by -762bps to 17.65% in 2025.
  • Business Quant data shows Return on Capital Employed for SLN at 17.65% in Q4 2025, 22.19% in Q3 2025, and 21.06% in Q2 2025.